• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
Addiction Treatment Forum

Addiction Treatment Forum

Addiction Treatment Forum reports on substance use news of interest to opioid treatment programs and patients in medication-assisted treatment.

  • Newsletter
  • Addiction Resources
  • Methadone
  • Buprenorphine
  • Patient Brochures
  • Events

In-House, On-Site Pharmacy Provides Convenience and Minimizes Stigma, Enhancing Retention

January 18, 2019 by Alison Knopf

In opioid treatment programs (OTPs) in the United States, all pharmacy is “in-house,” meaning that patients are dispensed medication by nurses in the facility. There is no need to go to an outside community pharmacy—and for methadone, it’s not even legal for pharmacies to dispense for treatment of opioid use disorder (OUD).

In Canada, however, methadone patients can—and do—go to community pharmacies for their methadone, which is dispensed by the pharmacist, often on a daily basis. But it’s better if they stay in their facility to get the medication—in Canada, the treatment facility can have its own on-site pharmacy—because they are more likely to stay in treatment.

David K. White, PhD, president and CEO of BayMark Health Services, which has OTPs in both the United States and Canada, discussed the importance of pharmacy with AT Forum, focusing on the benefits that result from an in-house pharmacy that ultimately improves retention.

“The main benefits are convenience and lack of stigma,” Dr. White told AT Forum. This applies to the pharmacy in the United States, as well as to the proprietary pharmacy offered in Baymark’s Canada programs. “Our pharmacists deal every day with people who need methadone, buprenorphine and naltrexone,” said Dr. White. “They have the specific answers our patients need at their fingertips.”

Study Links In-House Pharmacies With Better Retention

A study published last year in Drug and Alcohol Dependence found that patients who receive medication at in-house pharmacies are more likely to stay in treatment. When Canadian patients choose to use an outside pharmacy, the percentage remaining in treatment one year later drops to 12%, compared to 56% of patients who receive their medication at the in-house specialty pharmacies (the study was conducted at Baymark treatment programs in Ontario).

While there are no significant cost implications for the patient or the payer in terms of medication delivery, the costs related to poor treatment retention are huge, said Dr. White. “If we retain more patients in treatment, it’s helpful to the patient and it saves money,” he said. He noted  that studies in the United States show that for every dollar spent on treatment, 7 to 10 dollars are saved in costs related to criminal justice, medical problems, and work-related problems.

Most Baymark patients get methadone, but about 10 years ago some started receiving buprenorphine. Currently, about 6% of Baymark patients take buprenorphine.

Reassuring Patients

“The costs of methadone are low, and the setup of the pharmacy system isn’t that complicated,” said Dr. White. “The retention rates for the collocated pharmacy are huge.”

It is also reassuring to patients to get their medication with other methadone and buprenorphine patients, “as opposed to walking into a pharmacy and feeling stigmatized,” said Dr. White. “It’s important to have a sensitive group of staff who understand the addiction issue, particularly given all of the misinformation out there, and the unfortunate stigma of medication- assisted treatment, both within and outside of the industry,” he said. “It’s better not to have patients exposed to that, to have them walk in and be accepted.”

Reference

Gauthier G, Eibl JK, Marsh DC. Improved treatment-retention for patients receiving methadone dosing within the clinic providing physician and other health services (onsite) versus dosing at community (offsite) pharmacies. Drug Alcohol Depend. 2018; Oct 1;191:1-5. Epub 2018 May 31. doi:10.1016/j.drugalcdep.2018.04.029.

Filed Under: 2019, 29-8, Medication-Assisted Treatment (MAT), Newsletter

Primary Sidebar

Upcoming Events

CADCA 2023 Leadership Forum and SAMHSA’s Prevention Day
January 30-February 3, 2023

Washington, D.C.
http://cadca.org/forum2023

2023 Rx and Illicit Drug Summit
April 10-13, 2023

Atlanta, Georgia
https://www.rx-summit.com/

2023 ASAM conference
April 13-16, 2023

Washington, D.C.
https://annualconference.asam.org/

 

View More Upcoming Events…

ATForum.com

  • Newsletter
  • Addiction Resources
  • Rx Methadone & Safety
  • Patient Education Brochures
  • Events
  • Related Websites

Addiction Resources

  • Addiction and Recovery
  • Addiction Treatment Forum
  • Books and Booklets of Interest
  • Drug Screening and Testing
  • Evidence-Based Addiction Medicine
  • Federal Government
  • Health Care Reform
  • Hepatitis, HIV/AIDS
  • Medication-Assisted Treatment
  • Mental Health
  • Miscellaneous
  • Online Continuing Education Free Training Modules

Footer

Addiction Treatment Forum is produced by an independent medical communications agency. Commercial advertising is not accepted.
Published by Clinco Communications, Inc.
About Us
Contact Us
Privacy Policy
Terms of Use
Follow Us

Sign up for News!

© 2023 Addiction Treatment Forum · All Rights Reserved